Literature DB >> 1423922

Production of tumor necrosis factor-alpha and interleukin-6 in mice infected with group B streptococci.

G Teti1, G Mancuso, F Tomasello, M S Chiofalo.   

Abstract

Group B streptococci (GBS) are a leading cause of sepsis and meningitis in neonates. Since cytokines are thought to play an important role in septic shock, we have studied serum levels of tumor necrosis factor-alpha (TNF alpha) and interleukin-6 (IL-6) in BALB/c mice infected with type III GBS. TNF alpha and IL-6 were detected by the L929 cytotoxicity and the B9 proliferation assays, respectively, in serial serum samples obtained after infection. After i.p. challenge with an LD50, serum TNF alpha rose above baseline values as early as 3 hr, peaked at 7 hr, and returned to baseline values at 20 hr. IL-6 serum levels rose concomitantly with TNF alpha, peaking 8 hr after challenge. No serum TNF alpha activity was detected in the course of sublethal infections. However, a transient rise in TNF alpha levels was observed after i.v. inoculation of high numbers (greater than or equal to 1 x 10(8) of heat-killed GBS. When groups of mice were injected i.v. with a single dose of anti-TNF alpha rabbit serum 2 hr before challenge with an LD90 or LD30, no effect was noted in terms of survival, although the serum TNF alpha peak was completely abrogated. Serum TNF alpha does not seem to play an obligatory role in GBS-induced lethality of adult mice. However, further studies are needed to assess better the role of this cytokine in the pathogenesis of GBS sepsis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423922

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  9 in total

1.  Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis.

Authors:  L Tissi; M Puliti; R Barluzzi; G Orefici; C von Hunolstein; F Bistoni
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Regulatory role of interleukin-10 in experimental group B streptococcal arthritis.

Authors:  Manuela Puliti; Christina Von Hunolstein; Claudie Verwaerde; Francesco Bistoni; Graziella Orefici; Luciana Tissi
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

3.  Lipopolysaccharide-induced cytokine cascade and lethality in LT alpha/TNF alpha-deficient mice.

Authors:  F Amiot; C Fitting; K J Tracey; J M Cavaillon; F Dautry
Journal:  Mol Med       Date:  1997-12       Impact factor: 6.354

4.  Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to group B streptococci.

Authors:  D J Kwak; N H Augustine; W G Borges; J L Joyner; W F Green; H R Hill
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

5.  Roles of the bacterial cell wall and capsule in induction of tumor necrosis factor alpha by type III group B streptococci.

Authors:  J G Vallejo; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

6.  Cytokine mRNA profiles in mononuclear cells in acute aseptic meningoencephalitis.

Authors:  V Navikas; M Haglund; J Link; B He; L Lindqvist; S Fredrikson; H Link
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

7.  Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection.

Authors:  G Teti; G Mancuso; F Tomasello
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

8.  FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis.

Authors:  Menna R Clatworthy; Kenneth G C Smith
Journal:  J Exp Med       Date:  2004-02-23       Impact factor: 14.307

9.  Neutrophils Directly Recognize Group B Streptococci and Contribute to Interleukin-1β Production during Infection.

Authors:  Nastaran Mohammadi; Angelina Midiri; Giuseppe Mancuso; Francesco Patanè; Mario Venza; Isabella Venza; Annamaria Passantino; Roberta Galbo; Giuseppe Teti; Concetta Beninati; Carmelo Biondo
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.